Eruptive Lentigines Confined to Resolving Psoriatic Plaques Following Treatment with Guselkumab

Eruptive lentigines related to resolving psoriatic plaques has been well documented in the literature following successful treatment with multiple therapies. This is historically associated with light treatment but has been expanded to include other therapies such as anti-tumor necrosis factor therapies and, more recently, some biologic agents. Gusel-kumab (Tremfya) is an IgG1λ monoclonal antibody used in the treatment of plaque psoriasis with only 1 case of eruptive lentigines confined to resolving psoriatic plaques (ELRP) noted as a side effect. We present the second such case of ELRP associated with the successful treatment of plaque psoriasis with Guselkumab. This case study is significant because as biologic agents become more popular, it is critical to document all side effects of new therapeutic agents when encountered.